Encephalopathy and hyperammonemia associated with valproic acid

Journal of Pharmacy Technology

Volumn 21, Issue 6, 2005, Pages 348-350

  Yee, Jennie L ^a   Wong, David ^b   Ormiston, Thomas M ^c,d  

^a Blue Shield of California ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CHLORPROMAZINE; CLOZAPINE; DOCUSATE SODIUM; GABAPENTIN; GEMFIBROZIL; ISPAGULA; LORAZEPAM; PANTOPRAZOLE; TRIHEXYPHENIDYL; VALPROIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAND MAL EPILEPSY; HUMAN; HYPERAMMONEMIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; REVIEW; SIDE EFFECT;

EID: 28944441102     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250502100607     Document Type: Review

References (16)

1. Duarte J, Macias S, Coria F, Fernandez E, Claveria LE. Valproateinduced coma: case report and literature review. Ann Pharmacother 1993;27:582-3.
2. Eze E, Workman M, Donley B. Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatr Serv 1998;49:1358-9.
3. Warter JM, Brandt C, Marescaux C, Rumbach L, Micheletti G, Chabrier G, et al. The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology 1983;33:1136-40.
4. Feil D, Chuang K, Sultzer DL. Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatry 2002;10:476-8.
5. McCall M, Bourgeois A. Valproic acid-induced hyperammonemia. J Clin Psychopharmacol 2004;24:521-6.
6. Panikkar GP, Gilman SM. Valproate-induced hyperammonemia in the psychiatric setting: 2 cases. J Clin Psychiatry 1999;60:557-9.
7. Verrotti A, Greco R, Morgese G, Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 1999;29: 36-40.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
9. Thabet H, Brahmi N, Amamou M, Salah NB, Hedhili A. Hyperlactatemia and hyperammonemia in secondary effects of valproic acid poisoning (letter). Am J Emerg Med 2000;18:508.
10. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000;34:630-8. DOI 10.1345/aph.19242
11. Nelson DL, Cox MM. Lehninger principles of biochemistry. 3rd ed. New York: Worth Publishers, 2000:632-4.
12. Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000;54:230-2.
13. Longin E, Teich M, Koelfen W, Konig S. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 2002;43:451-4.
14. Latour P, Biraben A, Polard E, Bentue-Ferrer D, Beauplet A, Tribut O, et al. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both? Human Psychopharmacol 2004; 19:191-203.
15. Nicolai J, Smith SJ, Keunen RW. Simultaneous side effects of both clozapine and valproate. Intensive Care Med 2001;27:943. DOI 10.1007/s001340100937
16. Kifune A, Kubota F, Shibata N, Akata T, Kikuchi S. Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia 2000;41:909-12.